Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults With Recurrent or Refractory Ewing Sarcoma

NCT00470275 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00470275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00470275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults With Recurrent or Refractory Ewing Sarcoma
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
December 31, 2013
Enrollment
10 (actual)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma